BiotechTube
Paradigm Therapeutics

Paradigm Therapeutics

Cambridge, United States· Est.
paradigmtherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Paradigm Therapeutics is a private, clinical-stage biotech company singularly focused on developing Zorblesia™ (SD-101), a breakthrough topical therapy for all subtypes of Epidermolysis Bullosa (EB). The company acquired the global rights to this late-stage asset in 2023 and is advancing it toward a planned NDA submission in the second half of 2025, supported by strategic investments from Eshelman Ventures. Paradigm operates as a lean, development-centric organization aiming to deliver the first whole-body topical treatment for this devastating rare genetic skin disorder.

Rare Genetic DiseasesDermatology

Technology Platform

Asset-centric development of a proprietary topical formulation for whole-body application in fragile skin disorders.

Opportunities

Zorblesia™ addresses a severe unmet need in EB with only palliative care currently available, positioning it for premium pricing and rapid uptake upon approval.
The acquisition of global rights and Breakthrough Therapy designation create a clear path to a first-in-class whole-body topical treatment with significant market potential in a high-priority rare disease area.

Risk Factors

The company faces binary risk with its entire value dependent on a single late-stage asset; any delay or rejection of the NDA would be catastrophic.
As a pre-revenue company launching a first product, it also faces significant commercialization and market access challenges in a complex rare disease space.

Competitive Landscape

Current competition is limited to palliative wound care, but Paradigm faces emerging competition from companies developing advanced systemic, gene, and cell therapies for EB. Its success hinges on establishing Zorblesia™ as a foundational topical therapy that potentially works in combination with future modalities.

More companies in Small Molecule Drugs →More companies in United States →